Multiple studies have identified a number of molecular biomarkers that are prognostic for DCIS local recurrence rate including the status of HER-2 amplification (23), negative hormone receptor status (24, 25), and immunohistochemical detection of a range of biomarkers, including COX2 (26, 27), Ki67 (27), p16 (26–28), p53 (29, 30), p21 (31), and BNIP3 (32). The gene discussed is MKI67; the disease is ductal breast carcinoma in situ.